echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > Nature: New nano-vaccine is expected to prevent infections of various types of coronaviruses and mutants

    Nature: New nano-vaccine is expected to prevent infections of various types of coronaviruses and mutants

    • Last Update: 2021-05-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Written | Edited by xiao xia | Typeset by Wang Cong | In the 21st century, the world has been prone to outbreaks of infectious diseases caused by multiple coronaviruses-SARS, New Coronavirus and MERS Coronavirus.

    The β-coronavirus, which is transmitted in civet cats, bats and Malay pangolins, is genetically similar to SARS-CoV-1 and SARS-CoV-2, and infects human cells through human ACE2 receptors, which can cause severe acute respiratory syndrome The outbreak of SARS and MERS, as well as the pandemic of COVID-19.

    Cross-reactive antibodies that can neutralize a variety of β-coronaviruses and prevent or treat β-coronavirus infections have been isolated from SARS-CoV-1 infected persons, which provides a basis for the development of a β-coronavirus vaccine against SARS virus .

    In mice, vaccines that can induce cross-reactive antibodies to the coronavirus have also been reported.

    However, it is currently unclear whether primate vaccination can induce cross-reactive antibodies against SARS-CoV-1, β-coronavirus or SARS-CoV-2 virus.

    On May 10, 2021, the research team of Duke University School of Medicine published a research paper titled: Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses in Nature.

    The research has developed a nano-vaccine, supplemented with 3M-052 adjuvant, which can induce protective immunity against SARS-CoV-2 and β-coronavirus spreading in animals, and can prevent possible β-coronavirus pandemics in the future.
    , And provide a technical platform for the further development of pan-β-coronavirus vaccine.The Achilles' heel of coronaviruses is their receptor binding domain (RBD), located on the spike that connects the virus to the receptors of human cells.

    This binding site allows the virus to enter the body and cause infection, but it can also be targeted by antibodies.

    The research team identified a specific receptor binding domain site on SARS-CoV-2, which makes them extremely vulnerable to cross-reactive antibodies.

    Then, the research team designed a ferritin nanoparticle vaccine to inject five macaques.
    The ACE2 competitive binding test proved that the nano vaccine prevented COVID-19 infection.

    Compared with the current vaccine platform or human natural infection, the new vaccine also caused a higher level of neutralization in animals.

    As the SARS-CoV-2 variant B.
    1.
    1.
    7 is spreading globally, it is worthy of attention.

    The research team tested and found that the rhesus monkeys injected with the vaccine produced neutralizing antibodies against the mutant strain.

    The SARS-related coronavirus spreading in humans and animals remains a threat to future outbreaks.

    Therefore, the research team tested the neutralizing effect of rhesus monkey immune serum inoculated with RBD on SARS-CoV-1, bat CoV-WIV-1, and bat CoV-SHC014 viruses.

    After two immunizations, the rhesus monkeys produced antibodies that neutralized the above coronavirus.

    In order to determine the protective effect of the vaccine against coronavirus infection, the research team injected the vaccine into rhesus monkeys that had been infected with the coronavirus, and found that the symptoms of the virus infection were relieved, the inflammation was reduced, and the virus stopped replicating and spreading, proving that the vaccine can treat the coronavirus.
    Viral infection.

    In conclusion, RBD immunization with the Toll-like receptor agonist 3M-052 as an adjuvant can induce cross-reactive neutralizing antibodies against a variety of SARS-related human and bat β-coronaviruses in primates.

    The 3M-052 adjuvant RBD vaccine will be a promising pan-vaccine development platform, paving the way for the defense of the coronavirus to attack humans again.

    Link to the paper: open to reprint this article open to reprint: just leave a message in this article to inform 
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.